Great interim trial news... so shorting RNA is a time bomb... Lifting hold on new candidates in the current trial will add $10 to stock without squeeze...likely a double SP on the news with the aid of with flippers like you chasing to cover... make my day!

WATCH FOR BREAKOUT...above 6.76...pennies from 50MA... then to 7, and Blue Skys to $11.00

HOW MUCH DATA HAS PL supplied U. S. Military bought and continues to increase for Eastern Europe and UKRAINE surveillance ????

Looking for a 50% growth forecast in March ...

Acquisition target? IMO Likely!

Great buying opportunity...as daytraders short on low vol...watch recovery at eod...to $6 as shorts cover

...watch closely...if Russia invades Ukraine (IMO 90% likely)...Taiwan will be in play... then a Critical world crisis with U.S. (Biden) not having the balls to defend Taiwan.

PL will become more of a VITAL service to the U.S military than it is now...for drone surveillance of Russian and Chinese troop and naval movements...

IMO Look for a Defense Company quickly to acquire PL ... (IMO $20 or more)

With SpaceX tied at the hip with PL...its become a natural fit for acquisition by Elon!

Meanwhile, The more satellites launched, the more the margins and ebitda increases and the more exponential the price becomes.

imo...Merck's is a time bomb!

I agree... IMO LEO is far from "in hiding", but as PRs have indicated, company is reviewing data from the CT, addressing current opportunities, and exploring "others" (hopefully having to do with Brilacidin and synergies with "others" for advancement of indications on the runway)...

...as they say: "Stay Tuned"

looks like the Short Squeeze commencing!

And GOLDMAN lowered the price target to $60.00...(6X) from here. Some see things others don't.

Don't know about $30-$35 without positive news...but

IMO extremely oversold with $8.33 per share in cash ($450M) and the ability to license/acquire compound with pipeline in UC/UP Chrones as well as Skin Infection indication from another company which is on the runway with PhaseII/III and Phase III but without the funds to move expeditiously ... a licensing opportunity in the offing?

IMO see a rebound to $12-$15 for starters...after those funds/investors are finished booking losses to offset gains in 2021 and those with Margin calls who haven't liquidate finish doing so. We could have seen the low from booking loses and Margin liquidation at the eod and down to $8.50. IMO likely hit bottom today...but could retest tomorrow

You quote a prior board statement...noting IPIX, was having difficulty delivering (manufacturing/supply chain issues and) Brilacidin during the height of Covid ... (which is just now waning in the U.S.) quoting:

...Then you proceed to state..." Alpha CHOSE NOT TO PRIORITIZE their Brilacidin Clinical Trials (UP/Brilacidin) because they did not proceed with a drug that was not available to test???

No one can conclude delay in proceeding with UP/Brilacidin CT had anything to do with INTENT NOT TO PROCEED. What is clear Brilacidin was not available for those trials...Recent PRs appear to indicate that it is no longer a problem and Alpha is moving ahead.

In addition, Latest PRs on OM appear to be on course with a target of Q1 CT...as well as UC.

Looking for more commentary on recent CT and alternative delivery of Brilacidin...

Bradford...

Undoubtedly " he is equally disappointed but how can it be his fault the top-line data wasn’t met "

Amazing ignorance and theatrics over of "off with his head" because top-line was not met. If it failure of the top line in a clinical trial was deemed a "criminal" responsibility of the pharma CEO...there would be no Pharma Industry.

Bounty Hunters looking for Leo's head, and allegedly "screwed the pooch"...over the following statement in yesterday's PR:

When anyone reading the public information on the Trials Placebo/Brilacidin breakdown (both official CT sites and PR of the company) would KNOW...of the 120 patients included 60 received Brilacidin and 60 received SOC.

Hardly actionable...

Perhaps it could have been stated more clearly as...for those who know better, but wish to create an issue, where there is none.

"In the trial, 120 patients were treated, (and as CLEARLY STATED in the CT protocol, 60 receiving Placebo (SOC) and 60 receiving Brilacidin), with three-fourths of the Brilacidin administered patients receiving 5 days of study drug."

down 50%, but IMO Brilacidin still has too much opportunity in its pipeline to sell, especially with the pedigree behind Brilacidin in support of it's potential. I look forward to OM moving forward beginning Jan and 1st Quarter...

Obviously disappointed...but agree with both your observations, thesis, and position...I will not sell on this news...IMO more to come on Covid CT analysis...

Also, regardless of Covid...I am holding for the OM CT expected to be expedited in January quarter.

If IPIX rises to .50 on topline...DUE TO (WHAT WE ANTICIPATE) IS POSITIVE TOP LINE RESULTS...its going to $ Dollars...and not looking back from there!~

...under those conditions, its a fools game to attempt to FLIP and think to have a chance of getting back in...

Likely at that point (Selling at $.50) IMO a flipper/trader would be leaving 20X - 30X on the table...FOR BEGINNERS.

But the penny pinchers can't change their MOS...IMO to their loss.

Tom...fascinating article about Dr. Zasloff's discovery of frog peptide which is nature's immunity used to disrupt and destroy...the bacterial and viral cells surrounding frogs in their environment, which he discovered while researching the skin of frogs for their natural immunity.


IMO...Dr. Zasloff's quote in 1988...indicates that developing his peptide disease (bacterial and viral infections) by testing of peptide attributes and mechanisms HAS COME TO FRUITION 33 YEARS LATER...via TEAM DEGRADO'S DEVELOPMENT AND CLINICAL TRIALS BRILAICIDN for COVID-19 and Variants.

As CITED BY LEO in a previous PR... Dr. Zasloff acknowledged the validity of the bacterial and viral destructive mechanisms of Brilacidin (a DeNovo Peptide developed by Dr. DeGrado/Team) in stating:
...

The ABSSSI Clinical Trials demonstrated the efficacy of Brilacidin vs. bacteria cells (destroying the cells via creating an immediate electrical imbalance in the outer-cell). and IMO the CURRENT CLINICAL TRAILS are about to demonstrate the same for enveloped VIRAL CELLS (which is the structure of Covid-19 and the vast majority of Viruses)

Dr. Zasloff noted in 1988...


It would appear that "Dr. DeGrado/Team's" development of Brilacidin was inspired and spurred on by and Dr. Zasloff's frog peptide (magainin molecules) discovery.

A very similar description of the Destructive Mechanisms of Brilacidin to the Cell Structure of enveloped Bacteria and Virus cells...by DeGrado/TEAM...i.e. destabilizing the outer shell of the cells...much like a "pin popping a balloon" ... was made by Dr. Zasloff regarding the peptide (magainin) action he discovered:



...in the end, Brilacidin has two huge SCIENTIFIC ENDORSERS of its Mechanism for immediately destroying both Bacteria and Virus enveloped cells (almost all )...Dr. Zasloff and Dr. DeGrado ...one in the Discovery of Peptides and destruction of Bacteria/Viruses (and beyond) in the animal kingdom, and the later in the DEVELOPMENT OF DE NOVO peptide sequencing and the end product...BRILACIDIN

Know what you own!

The question is hardly "begs"...IPIX (LEO) IMO has been meticulous in Patent filings and protection...

...and for Covid-19? LEO has obviously had Dr. DeGrado by his side for quite a while, IMO well before Dr DeGrado accepted his position as Scientific Advisor to IPIX...collaborating and assisting in IPIX filing patent protections on new indication and extensions on old (to add years to protection)...would IMO be one of Dr. DeGrado's greatest values to IPIX...

...the question rates a big "Duh!" response.

Additionally...there is NO ONE that can compare to DeGrado with intricate knowledge of DeNova Peptides (since he was one of the primary developers and a continued researcher)...that could challenge a DeGrado assisted patent filings or extension on Brilacidin for any and every indication.

Chrismiss...interesting links...IMO Oral Mucositis is very low-hanging fruit for IPIX. With PHASE III Clinical Trials pushed out to Q-1, due to essentially product supply chain delays, ...this trial, IMO, will be a very simple, quick, and hugely successful...Clinical Trial...in an indication where every BP HAS FAILED!!!

IMO, OM has provided IPIX with an even greater opportunity to demonstrate Brilacidin's multi-functionality efficacy through the OM indication...and it is another sleeper in the IPIX/Brilacidin arsenal.

...and on top of that...Dr. DeGrado, co-developer of Brilacidin is hitting on ALL CYLINDERS...and the dynamic functionality of Brilacidin could push him over the top in this coming year...for the Nobel Prize for Chemistry/Medicine when all is said and done...

We are in the final count-down...for Top-line for Covid...with OM lining up behind it!

We are fortunate to have Dr. DeGrado's expertise and support as Scientific Advisor to IPIX, in the final stage and every indication going forward...

Again...KNOW WHAT YOU OWN!

Oh ... ok...you claim:

So 10%...15% or 20% would do it?...of course it would.

BUT YOU FAIL to acknowledge FDA was fully on board with Compassionate Use of Brilacidin after, and maybe before the end of the Clinical Trials...so since Drs requesting and receiving CU must report back to the FDA on impact... the FDA and IPIX know its impact of Brilacidin on the Critically Ill recipients of Brilacidin, which group has only a 5% survival rate...If 6 or 10 patients received Brilacidin via Compassionate Use and 3 or 5 survived...the question is ..." to what miracle would the FDA attribute an approximate 50% survival improvement?"

It's all speculation on my part (because Compassionate Use is not double-blinded)...but it should be noted that the FDA granting and encouraging (not stopping) Compassionate Use ... therefore, Compassionate Use results could be even more telling about Brilaicidin's attributes and efficacy...especially if the dosage was increased well beyond Clinical Trial protocol...

...all IMO...

We should learn a boatload in less than 7 trading days...

KNOW WHAT YOU OWN!

The flip side of this scheme is fodder for SEC criminal investigation...continuously trashing Stock/Company, then buying low and selling on the rebound...exactly what SEC is on the hunt for... its called encouraging a Dump...(calling company (IPIX) worthless or CEO (LEO) a crook, thereby "instigating" a DUMP), then buying the so-called "worthless" stock only to sell it on the rebound, after investors realize they were deceived!

...no different

The Russian CRO subcontracted by the U.S. CRO is owned by one of Russian's largest Pharmaceutical companies. They have, in the past, collaborated with a Russian Sovereign Investment Fund.

Based on the havoc wreaked on the Russian population by Covid-19/Delta, IMO it is a reasonable (speculation) assumption that any gamesmanship by FDA/BP in the US coupled with efficacy demonstrated on the TOPLINE of Brilacidin's Clinical Trial...would drive IPIX into their open arms...where "approval" and "licensing" could be possibly done very quickly. (Russian Pharma/Russian Gov "Sovereign Fund" = expedited approval and exclusive licensing possibilities in Eastern Europe and Western Asia).

...all IMO...of course.

FatAl...don't disagree with most of what you said:

...except we don't yet know the exact formulation request of and permitted by the FDA during Compassionate Use cases, which, due to the critical condition of the patients, could have been multiples of Clinical Trial dosing during these Compassionate Use cases.

IMO FDA could have learned (and maybe continuing to learn) a lot about the safety and dosage tolerance of Brilacidin during dosing Compassionate Use cases.

IMO...CT and Compassionate Use will likely "blow away" the bogus "safety" issues raised on this board...to the point where a Brilacidin "One-Shot Covid-Killer" dosage could be supported financially and fast-tracked...driven by DOD/CDC/FDA.

We already know through the GMU/RBL tests...that Brilacidin, present upon introduction of Covid-19 ... Destroys the covid virus and its variants...the definition of a prophylactic!

The truth is ... no one has documented with certainty that anyone on Brilacidin via "Compassionate Use" has died. We know through reports in the press (not Facebook) that a Covid-19 critically ill patient is in the hospital with collapsed lungs whose husband was fighting for Ivermectin...and according to the article was administered Brilacidin (assume at least one dose), a "hail Mary pass"...but we don't know if she received full dosing...etc.

We don't know the exact yet the number of Compassionate Use cases either ... in FL locale (or elsewhere) who have received FULL DOSAGE of Brilacidin...but it is a reasonable guess that there are likely more than have been rumored on social media...and we don't know how much greater the dosages of Brilacidin are being administered... based upon patients being in dire and critical condition (perhaps we will hear of evidence of greater efficacy with greater dosing!).

What we do know is via BREAK-THOUGH (Colin Powell) cases becoming more and more prevalent that VACCINES ARE NOT THE SOLUTION...

What good are vaccines for those in the "vulnerable" class whose bodies might not be able to produce sufficient antibodies after receiving the vaccine to combat the Covid?

DR. Gottlieb was interviewed on CNBC this AM and said "VACCINES will not be sufficient for the vulnerable population, their Immune systems are compromised and may not make the necessary anti-bodies to protect them"..."We need Therapeutics to act as a prophylactics"

Who are the "most vulnerable"?... According to Gottlieb, look no further than ANYONE WITH A COMPROMISED IMMUNE SYSTEM...due to AGE or PRE-EXISTING MEDICAL CONDITIONS...


...meaning... a huge swatch of the population are going to be in need of an EFFECTIVE PROPHYLACTIC THERAPEUTIC...which Brilacidin was identified potentially EFFECTIVE as one...by GMU/RBL

IMO ... Gottlieb's statement is the canary in the coal mine...It appears CDC/FDA (and BP) are finally realizing Covid destruction is not going to be curtailed with Vaccines and in the absence of EFFECTIVE AND BROAD THERAPEUTIC WHICH KILLS ON CONTACT (Prophylactic) That interview appears to be an indicator that the Med Community is finally going to head first into Therapeutics...

IMO Brilacidin's top-line demonstrating efficacy above Remdesivir will be lighting the rocket fuse... for Brilacidin...

Know what you own...IMO less than 10 days away from TOP-LINE

Dr. Bones...no need to fret over the "TWITTER" criptic comment.

...the reporting of (clearly conflicting statements) alleged events which are not even known to IPIX or LEO based upon ... a double-blinded study is not worth concern...

IMO ...the only anecdotal evidence of Brilacidin's efficacy OUTSIDE OF THE CLINICAL TRIALS...could only possibly come from "Compassionate Use" cases from Drs. who report back (and they must) to FDA on each case.

To qualify for Compassionate Use, by definition the patient has to be in CRITICAL CONDITION...on or about to go on a ventilator. There still is a 95% death rate for those on ventilators. 1 in 20 chance of surviving...

If after being administered Brilacidin in the dosage recommended or increased as requested by patient's physician...and survival occurs with Brilacidin as the patient walk's out of the hospital on his or her own accord...it would raise eyebrows at the hospital but it could simply be the 1 in 20 that make it. But if thereafter more Brilacidn Compassionate Use Patients survive ... IT WOULD RAISE MORE THAN AN EYEBROW...it would appear to be somewhat of a miracle, for example, if 4 out of 5 survived (assuming one on Facebook who reportedly died had full dosage...which some reported she did not) ... If ALL FULL DOSAGE PATIENTS, walked out of the hospital...AFTER BRILACIDIN...IMO the FDA would review that data IMO immediately WITH the TOPLINE deadline in considering EUA.

Without knowing the exact number of Brilacidin Compassionate Use "Critical Condition" survivors who received full dosing of Brilacidin ...it is conjecture as to whether Brilacidin's Compassionate Use results were the INVERSE of or at significantly better than SOC (ventilators/steroids) in those hospitals...

Perhaps the inquiry by the poster who was close to Admin at the Miami HospitalS could find out how many Brilacidin Compassionate Use patients survived and walked out the door.

IMO...that positive information is Worth at least $5.00 for starters...

Days away from Top Line results...

Know what you own!

The truth is...while the "recorded" short position might be 2.5M shares...the fact is, by definition, no one knows for sure what the Naked Short position is.

Whispers are that the same hedge fund involved in the Mako assault is still active...and known to management. IMO ...therein would lie the naked short position (could be hefty...and some elsewhere have calculated with credibility...by backtesting trades since shorting at $4+... that it as huge). It would also account for the tenacious and continuous commentary everywhere, by "non-holders," IGNORING FACTUALLY POSITIVE TESTING RESULTS OF BRILACIDIN at least 2 INDEPENDENT GOV LABORATORIES and with more taking up Brilacidin independently of IPIX...

Good Clinicial Trial results will certainly smoke out the issue... Excellent Clinical Trials results...WILL BURN THEM... I and many longs can't wait...and there are only be a "short" number of days for that wait.

Know what you own!

Good to get the facts straight!...

Brilacidin with "EXPANDED ACCESS PROGRAM" approval...and based on %...has a 76% chance of FDA Approval...of course with the good results which Longs expect based upon independent RBL results and its DeGrado/U of Penn Science...

For Newbies...below is a Good Summary of Brilacidin...up until Aug 13, 2021...

BUT....NOW CLINICAL TRIALS ARE COMPLETE AND We ARE ON THE RUNWAY WITH ENGINES RUNNING...and IMO based upon PR...TOP LINE likely anytime within 2 weeks...

https://www.precisionvaccinations.com/vaccines/brilacidin-covid-19-therapeutic

This is a very salient and relevant article by those who raise the issue of whether molnupiravir is in "competition" with Brilacidin.

Very "ON_TOPIC" as we near the Top Line Reporting of Brilacidin's Clinical Trials.

AS YOU NOTED IN THE PREVIOUS POSTING...Molnupiravir was TOTALLY INEFFECTIVE in Moderate to Severe Cases of COVID...where BRILACIDIN TRIALS WERE FOCUSED!

...and ONLY 50% more effective than the PLACEBO... Huhh? Playing statistics/percentage games...while trying to pump another potentially TOXIC DRUG into the American public?

Then we have the article...


The article posted...raises more serious issues about molnupiravir's Mutatgenic and Cancer-causing effects, which have not even been mentioned in reporting of Molnupiravir by Merck and the Medical/Scientific community, no less addressed by the mainstream media/financial news...What about MERCK SILENCE on these issues?... Actual conclusions that it is safe on Humans can only be played out with long-term testing...

AND FDA, as well as MERCK, RIDGEBACK...as well as GILEAD, know it!

IF THEY DIDN'T KNOW IT...then WHY WOULD MERCK EXCLUDE PREGNANT WOMEN FROM THEIR TRIALS ... as well as telling men to abstain from heterosexual intercourse"???

"Schinazi told Barron that he did not believe that molnupiravir should be given to pregnant women, or to young people of reproductive age until more data is available.

Merck’s trials of molnupiravir have excluded pregnant women; the scientists running the trial asked male participants to “abstain from heterosexual intercourse” while taking the drug, according to the federal government website that tracks clinical trials.

A paper published in the Journal of Infectious Diseases in May by Schinazi and scientists at the University of North Carolina reported that NHC caused mutations in animal cell cultures in a lab test designed to detect such mutations.

“The risks for the host may not be zero,” the authors concluded. “Evaluating the utility of this drug should be done in those likely to receive the greatest benefit, with monitoring provided to assess potential long-term genotoxic side effects.”

One of the paper’s authors, Dr. Shuntai Zhou, a scientist at the Swanstrom Lab at UNC, said that he and his colleagues had flagged their initial findings to Merck in July 2020, roughly a year before his paper was published.
“There is a concern that this will cause long-term mutation effects, even cancer,” Zhou says.
Zhou says that he is certain that the drug will integrate itself into the DNA of mammalian hosts. “Biochemistry won’t lie,” he says. “This drug will be incorporated in the DNA.”

What impact it will have when it’s there is unknown, given the various systems human cells use to limit the impact of mutations.
Merck scientists responded to the UNC paper in a subsequent issue of the Journal of Infectious Disease, saying that their tests of molnupiravir in animals had not found higher mutation rates. The Merck scientists also took issue with details of the UNC authors’ methods. In a reply, the UNC scientists stood by their methods, and wrote that they believed that molnupiravir should only be used in people at high risk of serious illness from Covid-19 until its long-term risks are better understood.
Some experts have advised caution on the part of Merck and regulators.
“Given the possibility that the drug could be incorporated into cellular DNA, it will be very important to demonstrate a lack of cancer in animal models and in humans,” says Nathaniel Landau, a professor in the department of microbiology at the NYU Grossman School of Medicine who is not involved in any of the NHC or molnupiravir research. “Even though it looks good in preliminary animal models, it will be important not to rush this into clinical use before being very confident that it does not cause cancer even at very low frequencies.”

Molnupiravir’s first brush with public attention, long before Merck began its collaboration with Ridgeback, came in May 2020, when the former head of the U.S. government’s Biomedical Advanced Research and Development Authority said in a whistleblower complaint that he had been pressured to provide funding for molnupiravir, then known as EIDD-2801, but had objected, partially due to safety concerns. The former BARDA head, Dr. Rick Bright, told Bloomberg this past March that the involvement of Merck had “softened” his concerns.

Dr. Rick Bright, told Bloomberg this past March that the involvement of Merck had “softened” his concern about MOLNUPEIRAVIR

the OLD RIDGEBACK "MUTATION" DRUG...

"Raymond Schinazi, an Emory University chemist who has extensively studied the active ingredient in EIDD-2801 but has no connection to DRIVE, notes that his former pharmaceutical company, Pharmasset, abandoned it in 2003 after discovering its mutagenic properties. Schinazi says the small chemical tweaks made to increase the ingredient’s bioavailability and transform it into EIDD-2801 are unlikely to change its mutagenicity. “Thank goodness someone is raising the red flag,” about EIDD-2801...

NOTHING TO SEE HERE!" ???

"Toxicity studies with EIDD-2801 have taken place in mice, rats, dogs, and nonhuman primates" (...TEETH MISSING, SKULLS PARTIALLY FORMED...)"Painter says, and the results have been shared with FDA and drug regulators in Europe."

How much credence will be given to this drug with FDA "EUA"...and statement by FDA that "it's safe" without long-term testing based upon already known facts of mutating effect? How much MUTATION tolerance is the POTENTIAL RECIPIENTS of these drugs willing to take?...

https://www.science.org/news/2020/05/emails-offer-look-whistleblower-charges-cronyism-behind-potential-covid-19-drug

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164695176

Can't wait for SEN. RAND PAUL TO GET ALL OVER THIS ONE!

MM are using M*K/Ridgeback to hit IPIX...M*K is a mild/moderate infection therapy with 50% greater efficacy than Placebo(Remdesivir)???
What is the real efficacy???

Brilacidin is Moderate to Severe infection ... days away...IMO we are looking for 85% greater efficacy vs Remdesivir/Placebo...

No evidence M*K would be effective in Moderate/Severe hospitalized patients ...

ps... Ridgeback's other problem has not been raised by MEDIA YET!

Remember: "Raymond Schinazi, an Emory University chemist who has extensively studied the active ingredient in EIDD-2801 but has no connection to DRIVE, notes that his former pharmaceutical company, Pharmasset, abandoned it in 2003 after discovering its mutagenic properties. Schinazi says the small chemical tweaks made to increase the ingredient’s bioavailability and transform it into EIDD-2801 are unlikely to change its mutagenicity. “Thank goodness someone is raising the red flag,” about EIDD-2801, Schinazi says.

”

Obviously UNTRUE...IMO just the opposite...

Compassionate Use Patients = CRITICAL CONDITION...likely days away from dying...and likely going on or on ventilators...

IMO...in spite of the condition and even death post due to ORGAN FAILURE FROM COVID ravaging their system... Brilacidin's effects against COVID will be evident...i.e eliminating the virus in the patient even patients on the cusp of death...eliminating the additional strain of the virus while the organs attempt to heal themselves...

It would be logical to assume that the younger the Critical Condition patient the more chance of survival...but much will be learned.

IMO...based upon PR's and RBL...we will find via the several (or more) Compassionate Use cases the board via FB has apparently learned about...BRILACIDIN demonstrates POSITIVE SYSTEMIC EFFECTS...even IF a patient expires.

ON THE OTHER HAND... the Brilacidin concluded CLINICAL TRIAL is populated with ONLY "moderate to severe"...likely NOT LIKELY WITH PATIENTS WHOSE ORGANS ARE LIKELY DAMAGED FROM COVID..."beyond no return" experienced by CRITICALLY ILL Patients...according to the protocol they were not in critical condition...and therefore the healthier, likely less organ impairment, and more opportunity for Brilacidin to do its wonders is afforded...

IMO look for great results shortly!...and

Know what your own!

GLTAL (Longs)

PS. Effectively eliminating the VIRUS while assisting the body opportunity to repair organs...is what a Therapeutic is supposed to do... It's NOT a Heart, Liver, Lung, or Kidney medicine, but it can aid attempts by the body by eliminating the Virus and its deleterious effects on those organs...

Empirics...you are right...a baseless and illogical post to which you responded:

It is so ridiculous... when you consider Alfasigma would lose its B (UP) license (including the "right of first refusal") if they failed to fulfill its obligation to implement Clinical Trials, ....the full license would revert back to revert back to IPIX, and its Right of First Refusal to buy B would expire.

With that loss is all the money invested by Alfa, thus far (and of course the upside on UP AND RIGHT OF FIRST REFUSAL ON B FOR OTHER INDICATIONS!!!

A potentially huge loss for Alfasigma...

IMO from PRs they are only waiting for delivery of Brilacidin formulation for UP...then P2 begins!

Remember...several indications for B coming to a head...OM a proven winner, UP on the runway with Alfa, Covid-19/Varants days away...and UC progressing toward next Phase...

Know what you own!...especially now!

CAN'T BE ANY CLEARER......another bogus issue


"...the Company disputes the underlying basis for these (plural) amounts and notified Dr. Menon in November 2019 of the Company’s intent not to pay them."

"Contingent Liability" is not an accrued liability... it's a potential liability...IN DISPUTE, AS STATED...but must be listed.

IMO...The reporting of it also reveals the defense against the claim...LEO obviously has determined that Menon went hog wild on this own "research" WITHOUT PRIOR APPROVAL...

Even if approved (which obviously they were not, since if so, the language would not have been included in the K), oftentimes...Billings times and services are not documented properly and are subject to billing abuses...

This happens all the time with large wall street Law Firms overbilling...A challenge to a Legal Billings Invoice inevitably leads
to settlement...often times 30-50%...(based on the billing of associates time for over 24 hours in a day period...a little evidence of billing abuse) AN in the event of "prior approval" required...the INVOICE GOES TO ZERO...

IMO...Menon knows it, ergo...no suit. Salary combined in same "claim"...renders it subject resolving both disputes together...unless he severs salary claim.

Why not sue for salary? Simple...that too could be in the dispute...if he was off doing research not authorized as a Rogue Employee...the company's salary "obligation" to him is questionable. Why pay hundreds of thousands $100-$200k in trying to enforce a "claim" when there are likely material issues with the claim. Better to make a demand and wait for the company to get a windfall and collect on a "nuisance claim".

But likely he knows the value of the intellectual property and progress of Brilacidin and K...why put pressure on his stock? Why try to damage his "investment"

IMO he is OBVIOUSLY A LONG...on IPIX!

You reference two (unrelated) entirely different scenarios...

Your question is unrelated to the statement highlighted below in the quote:

Poster's Statement refers to "Compassionate Use"...not EUA and your statement:

"But they weren't just treated with Brilacidin."...is MISLEADING*...

They had to be treated with all approved treatments (Remdesivir) AND THOSE TREATMENTS (SOC REMDESIVIR) would have FAILED!

By the time they are receiving BRILACIDIN under Compassionate Use...it is almost guaranteed REMDESIVIR IS OUT OF THEIR SYSTEM! NOTHING IS WORKING...a pre-requisite for the administration of Brilacidin.

*Compassionate Use of Brilacidin is NOT A COMBINATION OF REMDESIVIR and BRILACIDIN...which your statement implies...THAT IS NOT THE CASE!

A "slight of hands" logic...implying the application of "Clinical Trial SOC" to Compassionate Use..."standard"... total BS.

IMO Brilacidin administered to patients under Compassionate Use has been a PURE and STRAIGHT UP 5 days IV dosage ADMINISTRATION OF BRILACIDIN...to patients... and in all likelihood
...the multiple use of Brilacidin under Compassionate Use has yielded positive outcomes for the patients or at least the first. (What doctor is not going to check with the first Doctor who requested Brilacidin?)

Additionally...IMO FDA approval of Brilacdind for Compassionate Use in the several patients (so far) cited...were all U.S. Doctors requests and U.S. Hospital administrations...

IMO word and whispers of "positive results" will get around.

...and no Leo does not have to announce them...

MANY POSITIVE DEVELOPMENTS...BESIDES THE CLINICAL TRIAL FOR COVID-19 alone...PR shows ...RBL community all over BRILACIDIN


KNOW WHAT YOUR OWN...and don't listen to the FUD noise...

...ONWARD and UPWARD!

Brilacidin is showing expanded utility in the "non-enveloped virus" quadrant...with successful and expanded studies...

IMO "several" Gov/University labs are ALL OVER BRILACIDIN...

With several "compassionate use" cases...under Brilacidin's belt...it is obvious there are Clinicians who have heard of Brilacidin/Covid and found it worth the risk of use...look for them to spread any word of improvement...(IMO there likely was...if the first struck out...there likely would not have been a second or third...a tea leaves read.

My personal hope is that IPIX takes all the time it requires to assemble and analyze all the data...IMO the longer it takes, the more thorough the results...

Meanwhile, a base is being solidly established...but more importantly...more VIA SEVERAL GOV. LABORATORIES...DOCUMENTATION OF BRILACIDIN'S ROBUST RESPONSE IN LABS TO ALL VIRUSES...will be PUBLISHED....and Dr DeGrado's genius will be recognized, and longs rewarded...

IPIX and most Biotechs...have Never had a more acclaimed SCIENTIST who DEVELOPED/DISCOVERED Brilacidin (owned by IPIX), as SCIENTIFIC ADVISOR supporting the Clinical Trials process for FDA approval.

IMO Dr. Kessler (a straight shooter) KNOW HIM AND IT...and is one who is watching very closely to these Trials and Compassionate Use cases!

Read on...

William F. "Bill" DeGrado, Ph.D., is the Professor of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF) [1] and a member of the National Academy of Sciences.

He received a B.S. (chemistry) from Kalamazoo College and a Ph.D. (Chemistry) from the University of Chicago in 1977 working with Emil T. Kaiser and F. Kezdy. His graduate work focused on the design of the oxime resin for solid-phase synthesis,[2] which was used for synthesis of protected peptides and is still in use for various types of combinatorial chemistry today. He also used peptide design to demonstrate that melittin adopts an amphiphilic helical structure,[3] which is responsible for its membrane-disrupting activity.

He first held an industrial position at DuPont Central Research & Development (later DuPont Merck Pharmaceutical Company). He transitioned to academia in 1996, joining the University of Pennsylvania as the George W. Raiziss professor of biochemistry and biophysics and then moved to UCSF in 2011.

His published research includes contributions to the fields of protein design, synthesis of peptidomimetics, and characterization of membrane-active peptides and proteins, most notably the M2 protein.

The M2 proton channel from Influenza A virus. DeGrado’s early work with the groups of Robert Lamb and Larry Pinto established the overall structure and mechanism of the M2 proton channel,[4] which is the target of the anti-influenza drugs, amantadine and rimantadine. A decade later their crystallographic,[5][6] and NMR structures[7][8] defined the fine details of the binding site for these drugs and explained the mechanism of the growing problem of amantadine-resistance. With Michael Klein, Robert Lamb and Larry Pinto, DeGrado extensively characterized the physiological properties of many drug-resistant mutants of the channel, identified those most likely to lead to resistance, and designed new drugs to address the problem of drug-resistant forms of influenza A virus.[7][9]

Awards
1988 Du Vigneaud Award for Young Investigators in Peptide Research
1989 Protein Society Young Investigator Award
1992 Eli Lilly Award in Biological Chemistry
2005 The American Peptide Society Merrifield Award
2008 The ACS Ralph F. Hirschmann Award in Peptide Chemistry
2015 The Stein and Moore Award
2018 American Chemical Society Murray Goodman Memorial Prize[10]

References
"William Degrado, PhD". UCSF. Retrieved 18 January 2014.
"DeGrado, W. F., and Kaiser, E. T. J. Org. Chem. 40, 1295-1230". 1980.
"DeGrado, W. F., Kèzdy, F. J., and Kaiser, E. T. Design, synthesis, and characterization of a cytotoxic peptide with melittin-like activity, J. Am. Chem. Soc. 103, 679-681". 1981.
"Pinto, L. H., Dieckmann, G. R., Gandhi, C. S., Papworth, C. G., Braman, J., Shaughnessy, M. A., Lear, J. D., Lamb, R. A., and DeGrado, W. F. A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity, Proc. Natl. Acad. Sci. U.S.A. 94, 11301-11306". 1997.
"Stouffer, A. L., Acharya, R., Salom, D., Levine, A. S., Di Costanzo, L., Soto, C. S., Tereshko, V., Nanda, V., Stayrook, S., and DeGrado, W. F. Structural basis for the function and inhibition of an influenza virus proton channel, Nature 451, 596-599". 2008.
"Acharya, R., Carnevale, V., Fiorin, G., Levine, B. G., Polishchuk, A. L., Balannik, V., Samish, I., Lamb, R. A., Pinto, L. H., DeGrado, W. F., and Klein, M. L. Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus, Proc Natl Acad Sci U S A 107, 15075-15080". 2010.
"Wang, J., Wu, Y., Ma, C., Fiorin, G., Wang, J., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus, Proc. Natl. Acad. Sci. U.S.A. 110, 1315-1320". 2013.
"Cady, S. D., Schmidt-Rohr, K., Wang, J., Soto, C. S., DeGrado, W. F., and Hong, M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers, Nature 463, 689-692". 2010.
"Wang, J., Ma, C., Fiorin, G., Carnevale, V., Wang, T., Hu, F., Lamb, R. A., Pinto, L. H., Hong, M., Klein, M. L., and DeGrado, W. F. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2, J Am Chem Soc 133, 12834-12841". 2011.
"Recipients | ACS Division of Biological Chemistry Website". www.divbiolchem.org. Retrieved 2018-03-22.

External links
Web site of the DeGrado laboratory


PUBLISHED RESEARCH ARTICLE
418 results ...SOME BELOW:

1
Cite Share

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S.
Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub 2018 Oct 25.
PMID: 30449325 Free PMC article.

2
Cite Share

The avß1 integrin plays a critical in vivo role in tissue fibrosis.
Reed NI, Jo H, Chen C, Tsujino K, Arnold TD, DeGrado WF, Sheppard D.
Sci Transl Med. 2015 May 20;7(288):288ra79. doi: 10.1126/scitranslmed.aaa5094.
PMID: 25995225 Free PMC article.

3
Cite Share

De novo protein design, a retrospective.
Korendovych IV, DeGrado WF.
Q Rev Biophys. 2020 Feb 11;53:e3. doi: 10.1017/S0033583519000131.
PMID: 32041676 Free PMC article. Review.

4
Cite Share

Prion biology: implications for Alzheimer's disease therapeutics.
Condello C, DeGrado WF, Prusiner SB.
Lancet Neurol. 2020 Oct;19(10):802-803. doi: 10.1016/S1474-4422(20)30274-X. Epub 2020 Sep 16.
PMID: 32949533 No abstract available.

5
Cite Share

Dual antagonists of a5ß1/avß1 integrin for airway hyperresponsiveness.
Sundaram A, Chen C, Isik Reed N, Liu S, Ki Yeon S, McIntosh J, Tang YZ, Yang H, Adler M, Beresis R, Seiple IB, Sheppard D, DeGrado WF, Jo H.
Bioorg Med Chem Lett. 2020 Nov 15;30(22):127578. doi: 10.1016/j.bmcl.2020.127578. Epub 2020 Sep 29.
PMID: 33007395

6
Cite Share

Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates.
Boyce JH, Dang B, Ary B, Edmondson Q, Craik CS, DeGrado WF, Seiple IB.
J Am Chem Soc. 2020 Dec 23;142(51):21310-21321. doi: 10.1021/jacs.0c06987. Epub 2020 Dec 10.
PMID: 33301681 Free PMC article.

7
Cite Share

Allosteric cooperation in a de novo-designed two-domain protein.
Pirro F, Schmidt N, Lincoff J, Widel ZX, Polizzi NF, Liu L, Therien MJ, Grabe M, Chino M, Lombardi A, DeGrado WF.
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33246-33253. doi: 10.1073/pnas.2017062117. Epub 2020 Dec 14.
PMID: 33318174 Free PMC article.

8
Cite Share

Deep mutational scanning reveals the structural basis for a-synuclein activity.
Newberry RW, Leong JT, Chow ED, Kampmann M, DeGrado WF.
Nat Chem Biol. 2020 Jun;16(6):653-659. doi: 10.1038/s41589-020-0480-6. Epub 2020 Mar 9.
PMID: 32152544 Free PMC article.

9
Cite Share

Catalytic efficiency of designed catalytic proteins.
Korendovych IV, DeGrado WF.
Curr Opin Struct Biol. 2014 Aug;27:113-21. doi: 10.1016/j.sbi.2014.06.006. Epub 2014 Jul 19.
PMID: 25048695 Free PMC article. Review.

10
Cite Share

SNAC-tag for sequence-specific chemical protein cleavage.
Dang B, Mravic M, Hu H, Schmidt N, Mensa B, DeGrado WF.
Nat Methods. 2019 Apr;16(4):319-322. doi: 10.1038/s41592-019-0357-3. Epub 2019 Mar 25.
PMID: 30923372 Free PMC article.
Page 2

11
Cite Share

A defined structural unit enables de novo design of small-molecule-binding proteins.
Polizzi NF, DeGrado WF.
Science. 2020 Sep 4;369(6508):1227-1233. doi: 10.1126/science.abb8330.
PMID: 32883865 Free PMC article.

12
Cite Share

Signal transduction in histidine kinases: insights from new structures.
Bhate MP, Molnar KS, Goulian M, DeGrado WF.
Structure. 2015 Jun 2;23(6):981-94. doi: 10.1016/j.str.2015.04.002. Epub 2015 May 14.
PMID: 25982528 Free PMC article. Review.

13
Cite Share

Robust Sequence Determinants of a-Synuclein Toxicity in Yeast Implicate Membrane Binding.
Newberry RW, Arhar T, Costello J, Hartoularos GC, Maxwell AM, Naing ZZC, Pittman M, Reddy NR, Schwarz DMC, Wassarman DR, Wu TS, Barrero D, Caggiano C, Catching A, Cavazos TB, Estes LS, Faust B, Fink EA, Goldman MA, Gomez YK, Gordon MG, Gunsalus LM, Hoppe N, Jaime-Garza M, Johnson MC, Jones MG, Kung AF, Lopez KE, Lumpe J, Martyn C, McCarthy EE, Miller-Vedam LE, Navarro EJ, Palar A, Pellegrino J, Saylor W, Stephens CA, Strickland J, Torosyan H, Wankowicz SA, Wong DR, Wong G, Redding S, Chow ED, DeGrado WF, Kampmann M.
ACS Chem Biol. 2020 Aug 21;15(8):2137-2153. doi: 10.1021/acschembio.0c00339. Epub 2020 Aug 12.
PMID: 32786289 Free PMC article.

14
Cite Share

Engineering and design: editorial overview.
Kuhlman B, DeGrado WF.
Curr Opin Struct Biol. 2009 Aug;19(4):440-1. doi: 10.1016/j.sbi.2009.07.010. Epub 2009 Aug 13.
PMID: 19683427 Free PMC article. No abstract available.

15
Cite Share

beta-Peptides: from structure to function.
Cheng RP, Gellman SH, DeGrado WF.
Chem Rev. 2001 Oct;101(10):3219-32. doi: 10.1021/cr000045i.
PMID: 11710070 Review. No abstract available.

16
Cite Share

Structural basis for integrin alphaIIbbeta3 clustering.
Li R, Bennett JS, Degrado WF.
Biochem Soc Trans. 2004 Jun;32(Pt3):412-5. doi: 10.1042/BST0320412.
PMID: 15157149 Review.

17
Cite Share

Protein minimization: downsizing through mutation.
DeGrado WF, Sosnick TR.
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5680-1. doi: 10.1073/pnas.93.12.5680.
PMID: 8650151 Free PMC article. Review. No abstract available.

18
Cite Share

Protein design: a hierarchic approach.
Bryson JW, Betz SF, Lu HS, Suich DJ, Zhou HX, O'Neil KT, DeGrado WF.
Science. 1995 Nov 10;270(5238):935-41. doi: 10.1126/science.270.5238.935.
PMID: 7481798 Review.

19
Cite Share

Protein design, a minimalist approach.
DeGrado WF, Wasserman ZR, Lear JD.
Science. 1989 Feb 3;243(4891):622-8. doi: 10.1126/science.2464850.
PMID: 2464850 Review.

20
Cite Share

De novo designed synthetic mimics of antimicrobial peptides.
Scott RW, DeGrado WF, Tew GN.
Curr Opin Biotechnol. 2008 Dec;19(6):620-7. doi: 10.1016/j.copbio.2008.10.013. Epub 2008 Nov 17.
PMID: 18996193 Free PMC article. Review.
Page 3

21
Cite Share

De novo design, synthesis and characterization of membrane-active peptides.
Lear JD, Gratkowski H, DeGrado WF.
Biochem Soc Trans. 2001 Aug;29(Pt 4):559-64. doi: 10.1042/bst0290559.
PMID: 11498028 Review.
Our current level of understanding of membrane-protein folding is primitive, but it is beginning to advance. Previously [Choma, Gratkowski, Lear and DeGrado (2000) Nat. Struct. Biol. 7, 161-166], we described studies of the association in detergent micelles of short, simpl …

22
Cite Share

Design of self-assembling transmembrane helical bundles to elucidate principles required for membrane protein folding and ion transport.
Joh NH, Grigoryan G, Wu Y, DeGrado WF.
Philos Trans R Soc Lond B Biol Sci. 2017 Aug 5;372(1726):20160214. doi: 10.1098/rstb.2016.0214.
PMID: 28630154 Free PMC article. Review.

23
Cite Share

Influenza A M2 Inhibitor Binding Understood through Mechanisms of Excess Proton Stabilization and Channel Dynamics.
Watkins LC, DeGrado WF, Voth GA.
J Am Chem Soc. 2020 Oct 14;142(41):17425-17433. doi: 10.1021/jacs.0c06419. Epub 2020 Sep 29.
PMID: 32933245 Free PMC article.

24
Cite Share

Protein-directed self-assembly of a fullerene crystal.
Kim KH, Ko DK, Kim YT, Kim NH, Paul J, Zhang SQ, Murray CB, Acharya R, DeGrado WF, Kim YH, Grigoryan G.
Nat Commun. 2016 Apr 26;7:11429. doi: 10.1038/ncomms11429.
PMID: 27113637 Free PMC article.

25
Cite Share

Foldamers as versatile frameworks for the design and evolution of function.
Goodman CM, Choi S, Shandler S, DeGrado WF.
Nat Chem Biol. 2007 May;3(5):252-62. doi: 10.1038/nchembio876.
PMID: 17438550 Free PMC article. Review.

26
Cite Share

Protein-protein interactions in the membrane: sequence, structural, and biological motifs.
Moore DT, Berger BW, DeGrado WF.
Structure. 2008 Jul;16(7):991-1001. doi: 10.1016/j.str.2008.05.007.
PMID: 18611372 Free PMC article. Review.

27
Cite Share

Modeling transmembrane helical oligomers.
Dieckmann GR, DeGrado WF.
Curr Opin Struct Biol. 1997 Aug;7(4):486-94. doi: 10.1016/s0959-440x(97)80111-x.
PMID: 9266169 Review.

28
Cite Share

Peptide-Programmable Nanoparticle Superstructures with Tailored Electrocatalytic Activity.
Kang ES, Kim YT, Ko YS, Kim NH, Cho G, Huh YH, Kim JH, Nam J, Thach TT, Youn D, Kim YD, Yun WS, DeGrado WF, Kim SY, Hammond PT, Lee J, Kwon YU, Ha DH, Kim YH.
ACS Nano. 2018 Jul 24;12(7):6554-6562. doi: 10.1021/acsnano.8b01146. Epub 2018 Jun 4.
PMID: 29842775 Free PMC article.

29
Cite Share

Structural basis for proton conduction and inhibition by the influenza M2 protein.
Hong M, DeGrado WF.
Protein Sci. 2012 Nov;21(11):1620-33. doi: 10.1002/pro.2158. Epub 2012 Oct 9.
PMID: 23001990 Free PMC article. Review.

30
Cite Share

Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.
Wang J, Qiu JX, Soto C, DeGrado WF.
Curr Opin Struct Biol. 2011 Feb;21(1):68-80. doi: 10.1016/j.sbi.2010.12.002. Epub 2011 Jan 17.
PMID: 21247754 Free PMC article. Review.
Page 4

31
Cite Share

Designed metalloprotein stabilizes a semiquinone radical.
Ulas G, Lemmin T, Wu Y, Gassner GT, DeGrado WF.
Nat Chem. 2016 Apr;8(4):354-9. doi: 10.1038/nchem.2453. Epub 2016 Feb 15.
PMID: 27001731 Free PMC article.

32
Cite Share

Native-like and structurally characterized designed alpha-helical bundles.
Betz SF, Bryson JW, DeGrado WF.
Curr Opin Struct Biol. 1995 Aug;5(4):457-63. doi: 10.1016/0959-440x(95)80029-8.
PMID: 8528761 Review.

33
Cite Share

A long-lived Aß oligomer resistant to fibrillization.
Nick M, Wu Y, Schmidt NW, Prusiner SB, Stöhr J, DeGrado WF.
Biopolymers. 2018 Aug;109(8):e23096. doi: 10.1002/bip.23096. Epub 2018 Jan 10.
PMID: 29319162 Free PMC article.

34
Cite Share

Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity.
Schnaider L, Brahmachari S, Schmidt NW, Mensa B, Shaham-Niv S, Bychenko D, Adler-Abramovich L, Shimon LJW, Kolusheva S, DeGrado WF, Gazit E.
Nat Commun. 2017 Nov 8;8(1):1365. doi: 10.1038/s41467-017-01447-x.
PMID: 29118336 Free PMC article.

35
Cite Share

Folding of helical membrane proteins: the role of polar, GxxxG-like and proline motifs.
Senes A, Engel DE, DeGrado WF.
Curr Opin Struct Biol. 2004 Aug;14(4):465-79. doi: 10.1016/j.sbi.2004.07.007.
PMID: 15313242 Review.

36
Cite Share

The accommodation index measures the perturbation associated with insertions and deletions in coiled-coils: Application to understand signaling in histidine kinases.
Schmidt NW, Grigoryan G, DeGrado WF.
Protein Sci. 2017 Mar;26(3):414-435. doi: 10.1002/pro.3095. Epub 2017 Feb 23.
PMID: 27977891 Free PMC article. Review.

37
Cite Share

Designed peptides that assemble into cross-a amyloid-like structures.
Zhang SQ, Huang H, Yang J, Kratochvil HT, Lolicato M, Liu Y, Shu X, Liu L, DeGrado WF.
Nat Chem Biol. 2018 Sep;14(9):870-875. doi: 10.1038/s41589-018-0105-5. Epub 2018 Jul 30.
PMID: 30061717 Free PMC article.

38
Cite Share

Blue fluorescent amino acid for biological spectroscopy and microscopy.
Hilaire MR, Ahmed IA, Lin CW, Jo H, DeGrado WF, Gai F.
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6005-6009. doi: 10.1073/pnas.1705586114. Epub 2017 May 22.
PMID: 28533371 Free PMC article.

39
Cite Share

Design of peptides and proteins.
Degrado WF.
Adv Protein Chem. 1988;39:51-124. doi: 10.1016/s0065-3233(08)60375-7.
PMID: 3072869 Review. No abstract available.

40
Cite Share

X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance.
Thomaston JL, Konstantinidi A, Liu L, Lambrinidis G, Tan J, Caffrey M, Wang J, Degrado WF, Kolocouris A.
Biochemistry. 2020 Feb 4;59(4):627-634. doi: 10.1021/acs.biochem.9b00971. Epub 2020 Jan 13.
PMID: 31894969 Free PMC article.
Page 5

41
Cite Share

Proton-Induced Conformational and Hydration Dynamics in the Influenza A M2 Channel.
Watkins LC, Liang R, Swanson JMJ, DeGrado WF, Voth GA.
J Am Chem Soc. 2019 Jul 24;141(29):11667-11676. doi: 10.1021/jacs.9b05136. Epub 2019 Jul 12.
PMID: 31264413 Free PMC article.

42
Cite Share

The twists and turns of beta-peptides.
DeGrado WF, Schneider JP, Hamuro Y.
J Pept Res. 1999 Sep;54(3):206-17. doi: 10.1034/j.1399-3011.1999.00131.x.
PMID: 10517158 Review.

43
Cite Share

Modulating Integrin aIIbß3 Activity through Mutagenesis of Allosterically Regulated Intersubunit Contacts.
Tan SK, Fong KP, Polizzi NF, Sternisha A, Slusky JSG, Yoon K, DeGrado WF, Bennett JS.
Biochemistry. 2019 Jul 30;58(30):3251-3259. doi: 10.1021/acs.biochem.9b00430. Epub 2019 Jul 12.
PMID: 31264850 Free PMC article.

44
Cite Share

Transmembrane communication: general principles and lessons from the structure and function of the M2 proton channel, K? channels, and integrin receptors.
Grigoryan G, Moore DT, DeGrado WF.
Annu Rev Biochem. 2011;80:211-37. doi: 10.1146/annurev-biochem-091008-152423.
PMID: 21548783 Free PMC article. Review.

45
Cite Share

Genetically Introducing Biochemically Reactive Amino Acids Dehydroalanine and Dehydrobutyrine in Proteins.
Yang B, Wang N, Schnier PD, Zheng F, Zhu H, Polizzi NF, Ittuveetil A, Saikam V, DeGrado WF, Wang Q, Wang PG, Wang L.
J Am Chem Soc. 2019 May 15;141(19):7698-7703. doi: 10.1021/jacs.9b02611. Epub 2019 May 3.
PMID: 31038942 Free PMC article.

46
Cite Share

De novo designed transmembrane peptides activating the a5ß1 integrin.
Mravic M, Hu H, Lu Z, Bennett JS, Sanders CR, Orr AW, DeGrado WF.
Protein Eng Des Sel. 2018 May 1;31(5):181-190. doi: 10.1093/protein/gzy014.
PMID: 29992271 Free PMC article.

47
Cite Share

Synthesis and application of the blue fluorescent amino acid l-4-cyanotryptophan to assess peptide-membrane interactions.
Zhang K , Ahmed IA , Kratochvil HT , DeGrado WF , Gai F , Jo H .
Chem Commun (Camb). 2019 Apr 25;55(35):5095-5098. doi: 10.1039/c9cc01152h.
PMID: 30957824 Free PMC article.

48
Cite Share

Computational biology: Biosensor design.
DeGrado WF.
Nature. 2003 May 8;423(6936):132-3. doi: 10.1038/423132a.
PMID: 12736670 No abstract available.

49
Cite Share

De novo design and structural characterization of proteins and metalloproteins.
DeGrado WF, Summa CM, Pavone V, Nastri F, Lombardi A.
Annu Rev Biochem. 1999;68:779-819. doi: 10.1146/annurev.biochem.68.1.779.
PMID: 10872466 Review.

50
Cite Share

4-Cyanoindole-2'-deoxyribonucleoside as a Dual Fluorescence and Infrared Probe of DNA Structure and Dynamics.
Ahmed IA, Acharyya A, Eng CM, Rodgers JM, DeGrado WF, Jo H, Gai F.
Molecules. 2019 Feb 8;24(3):602. doi: 10.3390/molecules24030602.
PMID: 30744004 Free PMC article.
Page 6

51
Cite Share

Unique transmembrane domain interactions differentially modulate integrin avß3 and aIIbß3 function.
Litvinov RI, Mravic M, Zhu H, Weisel JW, DeGrado WF, Bennett JS.
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12295-12300. doi: 10.1073/pnas.1904867116. Epub 2019 Jun 3.
PMID: 31160446 Free PMC article.

52
Cite Share

Design of a switchable eliminase.
Korendovych IV, Kulp DW, Wu Y, Cheng H, Roder H, DeGrado WF.
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6823-7. doi: 10.1073/pnas.1018191108. Epub 2011 Apr 11.
PMID: 21482808 Free PMC article.

53
Cite Share

Proteins from scratch.
DeGrado WF.
Science. 1997 Oct 3;278(5335):80-1. doi: 10.1126/science.278.5335.80.
PMID: 9340760 No abstract available.

54
Cite Share

De Novo Design of Four-Helix Bundle Metalloproteins: One Scaffold, Diverse Reactivities.
Lombardi A, Pirro F, Maglio O, Chino M, DeGrado WF.
Acc Chem Res. 2019 May 21;52(5):1148-1159. doi: 10.1021/acs.accounts.8b00674. Epub 2019 Apr 11.
PMID: 30973707 Free PMC article.

55
Cite Share

Zinc-binding structure of a catalytic amyloid from solid-state NMR.
Lee M, Wang T, Makhlynets OV, Wu Y, Polizzi NF, Wu H, Gosavi PM, Stöhr J, Korendovych IV, DeGrado WF, Hong M.
Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):6191-6196. doi: 10.1073/pnas.1706179114. Epub 2017 May 31.
PMID: 28566494 Free PMC article.

56
Cite Share

Packing of apolar side chains enables accurate design of highly stable membrane proteins.
Mravic M, Thomaston JL, Tucker M, Solomon PE, Liu L, DeGrado WF.
Science. 2019 Mar 29;363(6434):1418-1423. doi: 10.1126/science.aav7541.
PMID: 30923216 Free PMC article.

57
Cite Share

Aß and tau prion-like activities decline with longevity in the Alzheimer's disease human brain.
Aoyagi A, Condello C, Stöhr J, Yue W, Rivera BM, Lee JC, Woerman AL, Halliday G, van Duinen S, Ingelsson M, Lannfelt L, Graff C, Bird TD, Keene CD, Seeley WW, DeGrado WF, Prusiner SB.
Sci Transl Med. 2019 May 1;11(490):eaat8462. doi: 10.1126/scitranslmed.aat8462.
PMID: 31043574 Free PMC article.

58
Cite Share

Constructing ion channels from water-soluble a-helical barrels.
Scott AJ, Niitsu A, Kratochvil HT, Lang EJM, Sengel JT, Dawson WM, Mahendran KR, Mravic M, Thomson AR, Brady RL, Liu L, Mulholland AJ, Bayley H, DeGrado WF, Wallace MI, Woolfson DN.
Nat Chem. 2021 Jul;13(7):643-650. doi: 10.1038/s41557-021-00688-0. Epub 2021 May 10.
PMID: 33972753 Free PMC article.

59
Cite Share

How calmodulin binds its targets: sequence independent recognition of amphiphilic alpha-helices.
O'Neil KT, DeGrado WF.
Trends Biochem Sci. 1990 Feb;15(2):59-64. doi: 10.1016/0968-0004(90)90177-d.
PMID: 2186516 Review.

60
Cite Share

Exposing the Nucleation Site in a-Helix Folding: A Joint Experimental and Simulation Study.
Acharyya A, Ge Y, Wu H, DeGrado WF, Voelz VA, Gai F.
J Phys Chem B. 2019 Feb 28;123(8):1797-1807. doi: 10.1021/acs.jpcb.8b12220. Epub 2019 Feb 14.
PMID: 30694671 Free PMC article.
Page 7

61
Cite Share

Photoactivatable protein labeling by singlet oxygen mediated reactions.
To TL, Medzihradszky KF, Burlingame AL, DeGrado WF, Jo H, Shu X.
Bioorg Med Chem Lett. 2016 Jul 15;26(14):3359-3363. doi: 10.1016/j.bmcl.2016.05.034. Epub 2016 May 12.
PMID: 27220724 Free PMC article.

62
Cite Share

Graphene Symmetry Amplified by Designed Peptide Self-Assembly.
Mustata GM, Kim YH, Zhang J, DeGrado WF, Grigoryan G, Wanunu M.
Biophys J. 2016 Jun 7;110(11):2507-2516. doi: 10.1016/j.bpj.2016.04.037.
PMID: 27276268 Free PMC article.

63
Cite Share

De novo design of helical bundles as models for understanding protein folding and function.
Hill RB, Raleigh DP, Lombardi A, DeGrado WF.
Acc Chem Res. 2000 Nov;33(11):745-54. doi: 10.1021/ar970004h.
PMID: 11087311 Free PMC article. Review.

64
Cite Share

How do helix-helix interactions help determine the folds of membrane proteins? Perspectives from the study of homo-oligomeric helical bundles.
DeGrado WF, Gratkowski H, Lear JD.
Protein Sci. 2003 Apr;12(4):647-65. doi: 10.1110/ps.0236503.
PMID: 12649422 Free PMC article. Review.

65
Cite Share

Nature-inspired design of motif-specific antibody scaffolds.
Koerber JT, Thomsen ND, Hannigan BT, Degrado WF, Wells JA.
Nat Biotechnol. 2013 Oct;31(10):916-21. doi: 10.1038/nbt.2672. Epub 2013 Aug 18.
PMID: 23955275 Free PMC article.

66
Cite Share

Computational design of a protein crystal.
Lanci CJ, MacDermaid CM, Kang SG, Acharya R, North B, Yang X, Qiu XJ, DeGrado WF, Saven JG.
Proc Natl Acad Sci U S A. 2012 May 8;109(19):7304-9. doi: 10.1073/pnas.1112595109. Epub 2012 Apr 25.
PMID: 22538812 Free PMC article.

67
Cite Share

Short peptides self-assemble to produce catalytic amyloids.
Rufo CM, Moroz YS, Moroz OV, Stöhr J, Smith TA, Hu X, DeGrado WF, Korendovych IV.
Nat Chem. 2014 Apr;6(4):303-9. doi: 10.1038/nchem.1894. Epub 2014 Mar 16.
PMID: 24651196 Free PMC article.

68
Cite Share

High-density grids for efficient data collection from multiple crystals.
Baxter EL, Aguila L, Alonso-Mori R, Barnes CO, Bonagura CA, Brehmer W, Brunger AT, Calero G, Caradoc-Davies TT, Chatterjee R, Degrado WF, Fraser JS, Ibrahim M, Kern J, Kobilka BK, Kruse AC, Larsson KM, Lemke HT, Lyubimov AY, Manglik A, McPhillips SE, Norgren E, Pang SS, Soltis SM, Song J, Thomaston J, Tsai Y, Weis WI, Woldeyes RA, Yachandra V, Yano J, Zouni A, Cohen AE.
Acta Crystallogr D Struct Biol. 2016 Jan;72(Pt 1):2-11. doi: 10.1107/S2059798315020847. Epub 2016 Jan 1.
PMID: 26894529 Free PMC article.

69
Cite Share

Glutamine Side Chain 13C-18O as a Nonperturbative IR Probe of Amyloid Fibril Hydration and Assembly.
Wu H, Saltzberg DJ, Kratochvil HT, Jo H, Sali A, DeGrado WF.
J Am Chem Soc. 2019 May 8;141(18):7320-7326. doi: 10.1021/jacs.9b00577. Epub 2019 Apr 24.
PMID: 30998340 Free PMC article.

70
Cite Share

Crystal structure of the drug-resistant S31N influenza M2 proton channel.
Thomaston JL, DeGrado WF.
Protein Sci. 2016 Aug;25(8):1551-4. doi: 10.1002/pro.2937. Epub 2016 May 17.
PMID: 27082171 Free PMC article.
Page 8

71
Cite Share

Salt bridges: geometrically specific, designable interactions.
Donald JE, Kulp DW, DeGrado WF.
Proteins. 2011 Mar;79(3):898-915. doi: 10.1002/prot.22927. Epub 2011 Jan 5.
PMID: 21287621 Free PMC article.

72
Cite Share

A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells.
Stöhr J, Wu H, Nick M, Wu Y, Bhate M, Condello C, Johnson N, Rodgers J, Lemmin T, Acharya S, Becker J, Robinson K, Kelly MJS, Gai F, Stubbs G, Prusiner SB, DeGrado WF.
Nat Chem. 2017 Sep;9(9):874-881. doi: 10.1038/nchem.2754. Epub 2017 Apr 3.
PMID: 28837163 Free PMC article.

73
Cite Share

Small molecule inhibitors of integrin alpha2beta1.
Choi S, Vilaire G, Marcinkiewicz C, Winkler JD, Bennett JS, DeGrado WF.
J Med Chem. 2007 Nov 1;50(22):5457-62. doi: 10.1021/jm070252b. Epub 2007 Oct 4.
PMID: 17915848 Free PMC article.

74
Cite Share

Tertiary templates for the design of diiron proteins.
Summa CM, Lombardi A, Lewis M, DeGrado WF.
Curr Opin Struct Biol. 1999 Aug;9(4):500-8. doi: 10.1016/S0959-440X(99)80071-2.
PMID: 10449377 Review.

75
Cite Share

Design of a Short Thermally Stable a-Helix Embedded in a Macrocycle.
Wu H, Acharyya A, Wu Y, Liu L, Jo H, Gai F, DeGrado WF.
Chembiochem. 2018 May 4;19(9):902-906. doi: 10.1002/cbic.201800026. Epub 2018 Mar 22.
PMID: 29417711 Free PMC article.

76
Cite Share

Amphiphilic polymethacrylate derivatives as antimicrobial agents.
Kuroda K, DeGrado WF.
J Am Chem Soc. 2005 Mar 30;127(12):4128-9. doi: 10.1021/ja044205+.
PMID: 15783168

77
Cite Share

De novo design of a hyperstable non-natural protein-ligand complex with sub-Å accuracy.
Polizzi NF, Wu Y, Lemmin T, Maxwell AM, Zhang SQ, Rawson J, Beratan DN, Therien MJ, DeGrado WF.
Nat Chem. 2017 Dec;9(12):1157-1164. doi: 10.1038/nchem.2846. Epub 2017 Aug 21.
PMID: 29168496 Free PMC article.

78
Cite Share

De novo design of a transmembrane Zn²?-transporting four-helix bundle.
Joh NH, Wang T, Bhate MP, Acharya R, Wu Y, Grabe M, Hong M, Grigoryan G, DeGrado WF.
Science. 2014 Dec 19;346(6216):1520-4. doi: 10.1126/science.1261172.
PMID: 25525248 Free PMC article.

79
Cite Share

X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case.
Thomaston JL, Wu Y, Polizzi N, Liu L, Wang J, DeGrado WF.
J Am Chem Soc. 2019 Jul 24;141(29):11481-11488. doi: 10.1021/jacs.9b02196. Epub 2019 Jul 11.
PMID: 31184871 Free PMC article.

80
Cite Share

De novo design of catalytic proteins.
Kaplan J, DeGrado WF.
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11566-70. doi: 10.1073/pnas.0404387101. Epub 2004 Aug 3.
PMID: 15292507 Free PMC article.
Page 9

81
Cite Share

A real-time all-atom structural search engine for proteins.
Gonzalez G, Hannigan B, DeGrado WF.
PLoS Comput Biol. 2014 Jul 31;10(7):e1003750. doi: 10.1371/journal.pcbi.1003750. eCollection 2014 Jul.
PMID: 25079944 Free PMC article.

82
Cite Share

De Novo Design, Solution Characterization, and Crystallographic Structure of an Abiological Mn-Porphyrin-Binding Protein Capable of Stabilizing a Mn(V) Species.
Mann SI, Nayak A, Gassner GT, Therien MJ, DeGrado WF.
J Am Chem Soc. 2021 Jan 13;143(1):252-259. doi: 10.1021/jacs.0c10136. Epub 2020 Dec 29.
PMID: 33373215 Free PMC article.

83
Cite Share

In vitro 0N4R tau fibrils contain a monomorphic ß-sheet core enclosed by dynamically heterogeneous fuzzy coat segments.
Dregni AJ, Mandala VS, Wu H, Elkins MR, Wang HK, Hung I, DeGrado WF, Hong M.
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16357-16366. doi: 10.1073/pnas.1906839116. Epub 2019 Jul 29.
PMID: 31358628 Free PMC article.

84
Cite Share

Computational design of a self-assembling ß-peptide oligomer.
Korendovych IV, Kim YH, Ryan AH, Lear JD, Degrado WF, Shandler SJ.
Org Lett. 2010 Nov 19;12(22):5142-5. doi: 10.1021/ol102092r. Epub 2010 Oct 14.
PMID: 20945888 Free PMC article.

85
Cite Share

Proximity-enhanced SuFEx chemical cross-linker for specific and multitargeting cross-linking mass spectrometry.
Yang B, Wu H, Schnier PD, Liu Y, Liu J, Wang N, DeGrado WF, Wang L.
Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11162-11167. doi: 10.1073/pnas.1813574115. Epub 2018 Oct 15.
PMID: 30322930 Free PMC article.

86
Cite Share

Inhibition of integrin a2ß1 ameliorates glomerular injury.
Borza CM, Su Y, Chen X, Yu L, Mont S, Chetyrkin S, Voziyan P, Hudson BG, Billings PC, Jo H, Bennett JS, Degrado WF, Eckes B, Zent R, Pozzi A.
J Am Soc Nephrol. 2012 Jun;23(6):1027-38. doi: 10.1681/ASN.2011040367. Epub 2012 Mar 22.
PMID: 22440900 Free PMC article.

87
Cite Share

Computational design of a ß-peptide that targets transmembrane helices.
Shandler SJ, Korendovych IV, Moore DT, Smith-Dupont KB, Streu CN, Litvinov RI, Billings PC, Gai F, Bennett JS, DeGrado WF.
J Am Chem Soc. 2011 Aug 17;133(32):12378-81. doi: 10.1021/ja204215f. Epub 2011 Jul 22.
PMID: 21780757 Free PMC article.

88
Cite Share

Antibacterial mechanism of action of arylamide foldamers.
Mensa B, Kim YH, Choi S, Scott R, Caputo GA, DeGrado WF.
Antimicrob Agents Chemother. 2011 Nov;55(11):5043-53. doi: 10.1128/AAC.05009-11. Epub 2011 Aug 15.
PMID: 21844313 Free PMC article.

89
Cite Share

Analysis and design of three-stranded coiled coils and three-helix bundles.
Schneider JP, Lombardi A, DeGrado WF.
Fold Des. 1998;3(2):R29-40. doi: 10.1016/S1359-0278(98)00011-X.
PMID: 9565750 Review.

90
Cite Share

Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective avß1 Integrin Inhibitors.
Reed NI, Tang YZ, McIntosh J, Wu Y, Molnar KS, Civitavecchia A, Sheppard D, DeGrado WF, Jo H.
ACS Med Chem Lett. 2016 Aug 30;7(10):902-907. doi: 10.1021/acsmedchemlett.6b00196. eCollection 2016 Oct 13.
PMID: 27774126 Free PMC article.
Page 10

91
Cite Share

Acid activation mechanism of the influenza A M2 proton channel.
Liang R, Swanson JMJ, Madsen JJ, Hong M, DeGrado WF, Voth GA.
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6955-E6964. doi: 10.1073/pnas.1615471113. Epub 2016 Oct 24.
PMID: 27791184 Free PMC article.

92
Cite Share

An assay suitable for high throughput screening of anti-influenza drugs.
Mao L, Wang J, DeGrado WF, Inouye M.
PLoS One. 2013;8(1):e54070. doi: 10.1371/journal.pone.0054070. Epub 2013 Jan 10.
PMID: 23326573 Free PMC article.

93
Cite Share

Light-induced helix formation.
Huang CY, He S, DeGrado WF, McCafferty DG, Gai F.
J Am Chem Soc. 2002 Oct 30;124(43):12674-5. doi: 10.1021/ja028084u.
PMID: 12392410

94
Cite Share

Pharmacologic Blockade of avß1 Integrin Ameliorates Renal Failure and Fibrosis In Vivo.
Chang Y, Lau WL, Jo H, Tsujino K, Gewin L, Reed NI, Atakilit A, Nunes ACF, DeGrado WF, Sheppard D.
J Am Soc Nephrol. 2017 Jul;28(7):1998-2005. doi: 10.1681/ASN.2015050585. Epub 2017 Feb 20.
PMID: 28220032 Free PMC article.

95
Cite Share

Crystallization of proton channel peptides.
Lovejoy B, Akerfeldt KS, DeGrado WF, Eisenberg D.
Protein Sci. 1992 Aug;1(8):1073-7. doi: 10.1002/pro.5560010812.
PMID: 1284681 Free PMC article.

96
Cite Share

De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures.
Dang B, Wu H, Mulligan VK, Mravic M, Wu Y, Lemmin T, Ford A, Silva DA, Baker D, DeGrado WF.
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10852-10857. doi: 10.1073/pnas.1710695114. Epub 2017 Sep 25.
PMID: 28973862 Free PMC article.

97
Cite Share

Artificial diiron proteins: from structure to function.
Calhoun JR, Nastri F, Maglio O, Pavone V, Lombardi A, DeGrado WF.
Biopolymers. 2005;80(2-3):264-78. doi: 10.1002/bip.20230.
PMID: 15700297

98
Cite Share

Peptide engineering. Catalytic molten globules.
DeGrado WF.
Nature. 1993 Oct 7;365(6446):488-9. doi: 10.1038/365488a0.
PMID: 8413599 No abstract available.

99
Cite Share

Spectroscopic and metal binding properties of a de novo metalloprotein binding a tetrazinc cluster.
Chino M, Zhang SQ, Pirro F, Leone L, Maglio O, Lombardi A, DeGrado WF.
Biopolymers. 2018 Aug;109(10):e23339. doi: 10.1002/bip.23229. Epub 2018 Sep 11.
PMID: 30203532 Free PMC article.

100
Cite Share

Polar networks control oligomeric assembly in membranes.
Tatko CD, Nanda V, Lear JD, Degrado WF.
J Am Chem Soc. 2006 Apr 5;128(13):4170-1. doi: 10.1021/ja055561a.
PMID: 16568959

It has been stated:

Hilarious: "1) No way brilacidin will be launched as a result of a 120 patient Phase II study, even if the results are spectacular (they won't be, at least not in the sense you imply)."

Brilacidin is on target for EUA with 120 patient trials...If it meets TOPLINE and proves to be as efficacious as expected. AFTER ALL...REMDESIVIR RECEIVED EUA AFTER FAUCI CHEATED FOR IT...switched TOP-LINE of TRAILS when Remedsivir was obviously failing on its original and urged EUA from the FDA...NOW IS REPORTED THAT IT WAS USELESS ALL ALONG...and even TOXIC.


MORE HILARIOUS... "2) FDA, like all smart people, know that an ounce of prevention is worth a pound of cure. Any therapeutic will always be a second line of defense after vaccines have failed to prevent a breakthrough infection"

...FDA "Smart People"???... KNOWS that an "ONCE OF PREVENTION IS WORTH A POUND OF CURE"...this is the SAME FDA APPROVING A "FAILED" and TOXI DRUG into the veins of the vulnerable?

"SMART PEOPLE"...maybe more like "COMPROMISED AND CONFLICTED" with BP who let Fauci pull a fast one on them...or were they co-conspirators?! (Even more Dangerous...if they ARE SMART...then they knew all along about REMDESIVIR's failures and toxicity...which is unfortunately likely.)

How smart will they look when they are forced to REVOKE REMDESIVIR'S APPROVAL?

...and ANOTHER AMUSING STATEMENT: therapeutic "will always be a second line of defense after vaccines have failed to prevent a breakthrough infection."

Brilacidin, due to its RBL results, is EXPECTED AlSO TO BE the FIRST LINE...PROPHYLACTIC!...IMO will prove second to none.

BRILAICIDIN's Prophylactic mechanism IS THE Big Threat to the BP Vaccine monopoly!

A Very entertaining post... It gave me a big laugh!

KNOW WHAT YOU OWN...

Crazy...ITS WORSE THAN..."ineffective"

... the proof is mounting that it's downright toxic ... and Fauci knew it.

Major hospital Administrator in a very large Brooklyn Hospital told me at a meeting when I asked what he thought of Remdesivir as a therapeutic...that Clinicians were experiencing many Remedsivir users returning to the hospital with liver and kidney damage...and it was an unspoken concern regarding use of Remedesivir ... but of course "if it saved lives vs liver damage...what choice was there"

IMO...now they will have a choice...BRILACIDIN...

AND...

IMO...with good "actual" results...as PR'd..."Inhaler" would be on the table from interested parties.

Now we are learning Fauci's science project (Remdesivir) which could never achieve efficacy for any indication... Actually Failed. Fauci changed TOP-Line requirements 14 days before the trial was ending...to a new bogus "Top-line" result...so it would not fail once more. In fact, now we know, it never reached the original goal of actually saving lives...

GILEAD is screwed...They desperately need to replace Veklury(REMDESIVIR)... IMO they are like a feral cat sitting at the back door of IPIX waiting for its new meal...BRILACIDIN.

The question is what will BRILACIDIN cost them?

Remember...its all about the science and clinical trials proving out what the RBL's learned and believe...

BRILACIDIN ...is the KEY!

IMO with and via TOP-LINE RESULTS of Brilacidin/Covid-19, we will soon receive CONFIRMATION OF DeGRADO THESIS ...and it will be exactly what Dr. DeGrado and the Polymedix team observed as supporting the efficacy of Brilacidin through its mechanism of producing the destruction of both Bacteria and Virus envelope cells (which Covid-19 and all Mutations are)...on contact!

There was commentary in Polymedix PR's and conferences... that Brilacidin was designed to attract negatively charged envelope cells...and upon contact "pop the dell, like a pin pops a balloon"...but it is not a "by chance" contact with the cells and their destruction would occur...

(IMMEDIATE AND TOTAL DESTRUCTION OF THE VIRUS ON CONTACT IS THE ONLY WAY TO GUARANTEE THE ELIMINATION OF THE ABILITY OF THE COVIE AND ITS VARIANTS TO MUTATE!)

The two (Brilacidin and Envelope Bacteria/Viral Cells) in "proximity" of one another, causes a "magnetic" effect...between the targeted cells (bacterial or viral cells) to be destructed and Brilacidin, i.e. bad cells are "attracted" to Brilacidin.

Add to that...the Systemic IV delivery (especially 5 days in a row)...IMO can show in the Clinical Trials...a very dramatic effect and significant efficacy against Covid-19 and its Variants (Russia had Delta Variant toward the end of trials)...

We should not be surprised and should not forget that...Brilacidin was "INTENTIONALLY DESIGNED" to work as described in the above...it just wasn't "Discovered" to "possibly" do it.

Additionally, with Brilacidin's superior SI, I would not be surprised if we learn that the DAILY DOSAGE (given 5 days in a row...for 75% of the patients) of Brilacidin/Covid-19 was the same as the ABSSSI Trials...which demonstrated superior efficacy over the SOC with only ONE IV DOSE.

In other words... with Brilacidin SI so high...it would not be surprising that the FDA would "let it rip" against Covid-19.

We will soon know the results! Keep smiling!

...and KNOW WHAT YOU OWN!

Let's put Brilacidin/IPIX and Covid-19 Clinical Trials as well as the VALUE OF IPIX/BRILACIDIN...in perspective...

1. Whether One, Two, Three or 1,000 employees...THE VALUE OF IPIX is in the Value of the INTELLECTUAL PROPERTIES (COMPOUNDS - Brilacidin and Kevertrin) it is moving through CLINICAL TRIALS...

2. BP buys INTELLECTUAL PROPERTIES...With successful trials...and if necessary, ONLY KEY SCIENTIFIC PERSONNEL. IMO they will probably give DeGrado a huge consulting contract or make an offer to join them in the C suite that he can't refuse. (IMO Leo and LONG investors will go off in the sunset with a spectacular return on Covid-19/Variant indication alone.

3. LEO and staff with "Contract" Personal have done an excellent job in progressing to and through SUCCESSFUL BRILACIDIN PHASE II CLINICAL TRIALS...for UP, UC, OM, ABSSSI and in raising funds ($13M-16M) to COMPLETE and REPORT on Covid-19 Trials, as well as funding product development for the other indications. IMO ...we are days away from revealing SUCCESS in destroying ... COVID-19 and its Variants in the trials. IPIX IS FAR FROM A ONE-TRICK PONY!

4. NO CEO or CHAIRMAN of a PUBLICALLY TRADED BIOTEC COMPANY is personally liable for an Unsuccessful Clinical Trial... IF THAT WERE THE CASE...IF THE RIDICULOUS ASSERTION FROM DETRACTORS OF IPIX/LEO WERE TRUE...WE WOULD NEVER HAVE A BIOTECH COMPANY CONDUCTING EVEN ONE CLINICAL TRIAL!

5. ALL PR's by IPIX (LEO) on Brilacidin/Covid-19 trials were fact-based reporting on RBLS TEST RESULTS, Developers Hypothesis, as well as previous commentary regarding SUCCESSFUL PHASE II TRIALS ON OTHER INDICATIONs and BRILACIDIN's path to probable SUCCESS...in /COVID-19 Clinical Trials...NO EXAGGERATION...(LEO IS NOT STUPID!)...

...and most importantly...IMO it is very likely the FDA would not permit the publishing of PR's which were not fact-based and consistent with what is known about Brilacidin's attributes at the time of publication. With all the censorship around Covid-19/Vaccines/Therapies...if ANYTHING stated wwere not FACTUAL...IMO FDA would have not permitted the PR or sanctioned IPIX with a C*YD treatment.

Know what you own!

ps for those who care...I believe the religious holiday ends today at sunset...Tomorrow could be interesting...

IMO...A Very Big "YES"!

watch!

It's a simple explanation...The classic formula for Manipulated Pump in share price =

"micro-float stock + news (appears great but nothing of financial substance) that can cause unwarranted excitement then pop in SH (maybe even short covering)"

manipulated pump in share price

Likely pull back to $7.00... then lower when they do a secondary... Watch out for the price of secondary, if below $7.00 more pain.

There will likely be a lot of long-term holders who didn't intend to be...IMO...a long road ahead to breakeven for some.

glta...

Disclosure: watched the open...just saw the close...no position and no intention of initiating. Not my game.

Cybermich...also IPIX could be held in the individual principals of Baker Bros. could be held in "individually"...no one knows unless you have access to private portfolio ...which no one does...

I personally know the children of a Principal of a Private Equity/Brokerage Firm which advertises on CNBC frequently who has a modest number of IPIX shares in his children's accounts...and is "waiting for the clinical trial outcome"...(he is also a neighbor of Sean Hannity).

Know what you own!

BRILACIDIN ...is the KEY!

IMO with and via TOP-LINE RESULTS of Brilacidin/Covid-19, we will soon receive CONFIRMATION OF DeGRADO THESIS ...and it will be exactly what Dr. DeGrado and the Polymedix team observed as supporting the efficacy of Brilacidin through its mechanism of producing the destruction of both Bacteria and Virus envelope cells (which Covid-19 and all Mutations are)...on contact!

There was commentary in Polymedix PR's and conferences... that Brilacidin was designed to attract negatively charged envelope cells...and upon contact "pop the dell, like a pin pops a balloon"...but it is not a "by chance" contact with the cells and their destruction would occur...

(IMMEDIATE AND TOTAL DESTRUCTION OF THE VIRUS ON CONTACT IS THE ONLY WAY TO GUARANTEE THE ELIMINATION OF THE ABILITY OF THE COVIE AND ITS VARIANTS TO MUTATE!)

The two (Brilacidin and Envelope Bacteria/Viral Cells) in "proximity" of one another, causes a "magnetic" effect...between the targeted cells (bacterial or viral cells) to be destructed and Brilacidin, i.e. bad cells are "attracted" to Brilacidin.

Add to that...the Systemic IV delivery (especially 5 days in a row)...IMO can show in the Clinical Trials...a very dramatic effect and significant efficacy against Covid-19 and its Variants (Russia had Delta Variant toward the end of trials)...

We should not be surprised and should not forget that...Brilacidin was "INTENTIONALLY DESIGNED" to work as described in the above...it just wasn't "Discovered" to "possibly" do it.

Additionally, with Brilacidin's superior SI, I would not be surprised if we learn that the DAILY DOSAGE (given 5 days in a row...for 75% of the patients) of Brilacidin/Covid-19 was the same as the ABSSSI Trials...which demonstrated superior efficacy over the SOC with only ONE IV DOSE.

In other words... with Brilacidin SI so high...it would not be surprising that the FDA would "let it rip" against Covid-19.

We will soon know the results! Keep smiling!

...and KNOW WHAT YOU OWN!